TALS News and Press, Talaris Therapeutics Inc. From 01/06/22

BOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disord...

BOSTON and LOUISVILLE, Ky., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disord...

Talaris Therapeutics (NASDAQ:TALS) shares have recovered from two consecutive days of losses after the company announced that it would be part of the NASDAQ Biotechnology Index, effective before the market open Monday. The NASDAQ Biotechnology Index tracks the performance of a group of biotec...

BOSTON and LOUISVILLE, Ky., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. , (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune disea...

Halvorsen's 13F portfolio value increased from $32.98B to $36.04B this quarter. The number of positions increased from 88 to 96. Viking Global added McDonald’s and increased General Electric, Humana, Brookfield Asset Management, and Parker Hannifin while dropping Aon plc during...

High-resolution allele typing at six loci found Talaris Therapeutics' (NASDAQ:TALS) FCR001 induced durable immune tolerance in patients undergoing living donor kidney transplant. The tolerance was seen in highly mismatched related and unrelated recipients. In DNA samples from a phase 2 trial,...

BOSTON and LOUISVILLE, Ky., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. , (Nasdaq: TALS), a late-clinical stage cell therapy company, today presented a new analysis of HLA mismatching between donors and recipients participating in the Company’s Phase 2 trial in l...

BOSTON and LOUISVILLE, Ky., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. , (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune disea...

The following slide deck was published by Talaris Therapeutics, Inc. in conjunction with this event. For further details see: Talaris Therapeutics (TALS) Investor Presentation - Slideshow

Talaris Therapeutics (NASDAQ:TALS): Q3 GAAP EPS of -$0.32 misses by $0.06. Cash, cash equivalents and marketable securities of $254.7M Press Release For further details see: Talaris Therapeutics EPS misses by $0.06